keyword
MENU ▼
Read by QxMD icon Read
search

drug rash

keyword
https://www.readbyqxmd.com/read/28097858/-the-current-status-of-patient-safety-in-argentina-cross-sectional-study
#1
Lucrecia Arpí, Néstor D Panattieri, Cristina Godio, Verónica Sabio Paz, Nora Dackiewicz
BACKGROUND: Patient safety is a priority for healthcare organizations. For the PRONAP´s 2013 final exam, the Quality & Patient Safety Subcommittee and the PRONAP managers designed a survey to be answered by pediatrician students nationwide. It was destined to evaluate attitudes, practices and safety conditions in which they worked. AIM: To assess the current state of practices in patient safety. MATERIAL AND METHODS: Setting and sample: PRONAP students (7,438 pediatrician nationwide) who answered 2013 final exam...
1, 2017: Archivos Argentinos de Pediatría
https://www.readbyqxmd.com/read/28076589/time-volunteered-on-community-health-activities-by-brigadistas-in-nicaragua
#2
Meredith Adamo, Dixmer Rivera, Rashed Shah, Jeanne Koepsell, Leonel Martínez, Justo Pastor Ortiz, Carlos José Jarquín Navarrete, David R Marsh
Objective: To report on how brigadistas ("health brigadiers") in Nicaragua volunteer their time before the introduction of expanded responsibilities (beyond the scope of integrated community case management (iCCM)) for sick children 2-59 months old. Methods: Three complete teams of brigadistas (n = 12 brigadistas total) were selected from remote communities in the department of Matagalpa. Each respondent brigadista was interviewed privately regarding the frequency and duration (i...
November 2016: Revista Panamericana de Salud Pública, Pan American Journal of Public Health
https://www.readbyqxmd.com/read/28073844/fda-approval-of-nivolumab-for-the-first-line-treatment-of-patients-with-brafv600-wild-type-unresectable-or-metastatic-melanoma
#3
Julia A Beaver, Marc R Theoret, Sirisha Mushti, Kun He, Meredith Libeg, Kirsten Goldberg, Rajeshwari Sridhara, Amy E McKee, Patricia Keegan, Richard Pazdur
On November 23, 2015, the U.S. Food and Drug Administration approved nivolumab (OPDIVO®, Bristol Myers Squibb, Co.) as a single agent for the first-line treatment of patients with BRAFV600 wild-type, unresectable or metastatic melanoma. An international, double-blind, randomized (1:1) trial conducted outside of the U.S. allocated 418 patients to receive nivolumab 3mg/kg intravenously every 2 weeks (n=210) or dacarbazine 1000mg/m2 intravenously every 3 weeks (n=208). Patients with disease progression who met protocol-specified criteria (~25% of each trial arm) were permitted to continue with the assigned treatment in a blinded fashion until further disease progression is documented...
January 10, 2017: Clinical Cancer Research: An Official Journal of the American Association for Cancer Research
https://www.readbyqxmd.com/read/28069279/masitinib-for-treatment-of-severely-symptomatic-indolent-systemic-mastocytosis-a-randomised-placebo-controlled-phase-3-study
#4
Olivier Lortholary, Marie Olivia Chandesris, Cristina Bulai Livideanu, Carle Paul, Gérard Guillet, Ewa Jassem, Marek Niedoszytko, Stéphane Barete, Srdan Verstovsek, Clive Grattan, Gandhi Damaj, Danielle Canioni, Sylvie Fraitag, Ludovic Lhermitte, Sophie Georgin Lavialle, Laurent Frenzel, Lawrence B Afrin, Katia Hanssens, Julie Agopian, Raphael Gaillard, Jean-Pierre Kinet, Christian Auclair, Colin Mansfield, Alain Moussy, Patrice Dubreuil, Olivier Hermine
BACKGROUND: Indolent systemic mastocytosis, including the subvariant of smouldering systemic mastocytosis, is a lifelong condition associated with reduced quality of life. Masitinib inhibits KIT and LYN kinases that are involved in indolent systemic mastocytosis pathogenesis. We aimed to assess safety and efficacy of masitinib versus placebo in severely symptomatic patients who were unresponsive to optimal symptomatic treatments. METHODS: In this randomised, double-blind, placebo-controlled, phase 3 study, we enrolled adults (aged 18-75 years) with indolent or smouldering systemic mastocytosis, according to WHO classification or documented mastocytosis based on histological criteria, at 50 centres in 15 countries...
January 6, 2017: Lancet
https://www.readbyqxmd.com/read/28068177/safety-profile-of-nivolumab-monotherapy-a-pooled-analysis-of-patients-with-advanced-melanoma
#5
Jeffrey S Weber, F Stephen Hodi, Jedd D Wolchok, Suzanne L Topalian, Dirk Schadendorf, James Larkin, Mario Sznol, Georgina V Long, Hewei Li, Ian M Waxman, Joel Jiang, Caroline Robert
Purpose We conducted a retrospective analysis to assess the safety profile of nivolumab monotherapy in patients with advanced melanoma and describe the management of adverse events (AEs) using established safety guidelines. Patients and Methods Safety data were pooled from four studies, including two phase III trials, with patients who received nivolumab 3 mg/kg once every 2 weeks. We evaluated rate of treatment-related AEs, time to onset and resolution of select AEs (those with potential immunologic etiology), and impact of select AEs and suppressive immune-modulating agents (IMs) on antitumor efficacy...
November 14, 2016: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/28067684/diarrhea-after-allogeneic-stem-cell-transplantation-beyond-graft-versus-host-disease
#6
Katarzyna Robak, Joanna Zambonelli, Jaroslaw Bilinski, Grzegorz W Basak
Diarrhea constitutes a frequent and often debilitating complication of allogeneic hematopoietic cell transplantation (alloHCT). Especially when accompanied by jaundice, skin rash, and symptoms of the upper gastrointestinal tract, diarrhea strongly suggests emergence of acute graft-versus-host disease (GvHD), which is a serious immune complication of the procedure, with possible fatal consequences. However, especially when diarrhea occurs as an isolated symptom, the other causes must be excluded before initiation of GvHD treatment with immune-suppressive drugs...
January 6, 2017: European Journal of Gastroenterology & Hepatology
https://www.readbyqxmd.com/read/28063028/her2-positive-metastatic-breast-cancer-patients-receiving-pertuzumab-in-a-community-oncology-practice-setting-treatment-patterns-and-outcomes
#7
Nicholas J Robert, Hans-Peter Goertz, Pooja Chopra, Xiaolong Jiao, Bongin Yoo, Debra Patt, Vincent Antao
BACKGROUND: Pertuzumab (Perjeta(®)), a HER2/neu receptor antagonist, was approved by the US Food and Drug Administration in June 2012 for use in the first-line setting for patients with HER2-positive metastatic breast cancer (mBC). OBJECTIVE: This retrospective study investigated the clinical and demographic characteristics, treatment patterns, safety, and clinical outcomes for patients with HER2-positive mBC who received pertuzumab in the first-line setting in US community oncology practices...
January 6, 2017: Drugs—Real World Outcomes
https://www.readbyqxmd.com/read/28060046/serious-adverse-reactions-from-anti-tuberculosis-drugs-among-599-children-hospitalized-for-tuberculosis
#8
Yiyuan Li, Yu Zhu, Qin Zhong, Xiaojun Zhang, Min Shu, Chaomin Wan
BACKGROUNDS: The purpose of the study was to summarize the clinical characteristics of serious adverse reactions (ARs) related to anti-tuberculosis (TB) drugs in children hospitalized for TB. A comprehensive understanding of these drug-related ARs may serve to improve patient prognosis. METHOD: Inpatients diagnosed with TB from 2008 to 2013 were enrolled retrospectively. The patients' demographics, diagnosis and ARs were recorded and analyzed for comprehensive evaluation...
January 3, 2017: Pediatric Infectious Disease Journal
https://www.readbyqxmd.com/read/28052686/henoch-sch%C3%A3-nlein-purpura-as-a-rare-cause-of-an-acute-abdomen
#9
M Davies, M Nanda Kumar, V Shetty, P Mitchell
A 52-year-old man presented with a purpuric rash affecting his legs and hypertension. He was diagnosed with Henoch-Schönlein purpura and discharged with non-steroidal anti-inflammatory drugs. Three weeks later, he presented again with loss of appetite and vomiting before developing abdominal pain with pyrexia of 38.5°C and rigors. On examination, he was hypotensive with a distended abdomen and a national early warning score of 6. Computed tomography revealed enteropathy of Henoch-Schönlein purpura. The patient deteriorated and went for an emergency laparotomy, where 30cm of ischaemic small bowel was resected...
January 4, 2017: Annals of the Royal College of Surgeons of England
https://www.readbyqxmd.com/read/28049375/comparative-effectiveness-of-treatment-choices-for-graves-hyperthyroidism-a-historical-cohort-study
#10
Vishnu Sundaresh, Juan P Brito, Prabin Thapa, Rebecca S Bahn, Marius N Stan
Introduction The optimum therapy for Graves' Disease (GD) is chosen following discussion between physician and patient regarding benefits, drawbacks, potential side effects, and logistics of the various treatment options and takes into account patient values and preferences. This cohort study aimed to provide useful information for this discussion regarding the usage, efficacy and adverse effect profile of radioactive iodine (RAI), antithyroid drugs (ATDs), and thyroidectomy in a tertiary healthcare facility...
January 3, 2017: Thyroid: Official Journal of the American Thyroid Association
https://www.readbyqxmd.com/read/28043323/antiviral-medications-in-seasonal-and-pandemic-influenza
#11
Regine Lehnert, Mathias Pletz, Annicka Reuss, Tom Schaberg
BACKGROUND: Amantadine, oseltamivir, and zanamivir are currently available in Germany for the prevention and treatment of influenza. We review their efficacy and side-effect profiles. METHODS: This review is based on pertinent randomized and controlled trials (RCTs) and systematic reviews retrieved by a systematic literature search, and on other relevant literature. RESULTS: The efficacy of antiviral drugs for the prevention of symptomatic influenza ranges from 60% to 90% (number needed to treat [NNT], 8-89) depending on the population and type of drug in question...
November 25, 2016: Deutsches Ärzteblatt International
https://www.readbyqxmd.com/read/28035758/genotypic-tropism-testing-of-proviral-dna-to-guide-maraviroc-initiation-in-aviraemic-subjects-48-week-analysis-of-results-from-the-protest-study
#12
E Poveda, J Hernández-Quero, M J Pérez-Elías, M A Ribas, O J Martínez-Madrid, J Flores, J Navarro, F Gutiérrez, M García-Deltoro, A Imaz, A Ocampo, A Artero, F Blanco, E Bernal, J Pasquau, C Mínguez-Gallego, N Pérez, A Aiestaran, F García, R Paredes
OBJECTIVES: Maraviroc (MVC) is a suitable drug for aviraemic subjects on antiretroviral treatment (ART) developing toxicity. Its prescription requires prior tropism testing. It is unknown if proviral DNA genotypic tropism testing is reliable for guiding MVC initiation in aviraemic subjects, so this study was carried out to address this issue. METHODS: PROTEST was a phase 4, prospective, single-arm clinical trial carried out in 24 HIV care centres in Spain. MVC-naïve HIV-1-infected patients with HIV-1 RNA < 50 copies/mL on stable ART during the previous 6 months who required an ART change because of toxicity and who had R5 HIV, as determined by proviral DNA genotypic tropism testing, initiated MVC with two nucleoside reverse transcriptase inhibitors (NRTIs) and were followed for 48 weeks...
December 30, 2016: HIV Medicine
https://www.readbyqxmd.com/read/28031425/phase-ib-study-of-safety-and-pharmacokinetics-of-the-pi3k-inhibitor-sar245408-with-the-her3-neutralizing-human-antibody-sar256212-in-patients-with-solid-tumors
#13
Vandana G Abramson, Jeffrey G Supko, Tarah Ballinger, James M Cleary, John F Hilton, Sara Tolaney, Nicole G Chau, Daniel C Cho, Joanne J Lager, Joseph Pearlberg, Geoffrey I Shapiro, Carlos L Arteaga
PURPOSE: This phase Ib study was designed to determine the maximum tolerated dose, safety, preliminary efficacy, and pharmacokinetics of the HER3 (ErbB3) monoclonal antibody SAR256212 in combination with the oral phosphoinositide 3-kinase (PI3K) inhibitor SAR245408 for patients with metastatic or locally advanced solid tumors. EXPERIMENTAL DESIGN: Patients received the combination of intravenous SAR256212 and oral SAR245408 in a 3+3 dose escalation design until occurrence of disease progression or dose-limiting toxicity...
December 28, 2016: Clinical Cancer Research: An Official Journal of the American Association for Cancer Research
https://www.readbyqxmd.com/read/28027794/intraperitoneal-vancomycin-plus-either-oral-moxifloxacin-or-intraperitoneal-ceftazidime-for-the-treatment-of-peritoneal-dialysis-related-peritonitis-a-randomized-controlled-pilot%C3%A2-study
#14
Rong Xu, Zhikai Yang, Zhen Qu, Huan Wang, Xue Tian, David W Johnson, Jie Dong
BACKGROUND: Intraperitoneal administration of antibiotics is recommended as a first treatment for managing peritoneal dialysis (PD)-related peritonitis. However, the efficacy of oral administration of quinolones has not been well studied. STUDY DESIGN: Randomized controlled pilot study. SETTING & PARTICIPANTS: 80 eligible patients with PD-related peritonitis from Peking University First Hospital (40 in each arm). INTERVENTION: Intraperitoneal vancomycin, 1g, every 5 days plus oral moxifloxacin, 400mg, every day (treatment group) versus intraperitoneal vancomycin, 1g, every 5 days plus intraperitoneal ceftazidime, 1g, every day (control group)...
December 24, 2016: American Journal of Kidney Diseases: the Official Journal of the National Kidney Foundation
https://www.readbyqxmd.com/read/28011887/sweet-syndrome-a-painful-reality
#15
Uqba Khan, Humaira Rizvi, Farman Ali, Daniel Lebovic
Sweet syndrome is a rare disorder that is manifested by constellation of clinical features, including fever, neutrophilic leucocytosis, raised painful plaques on skin and dermal infiltration by neutrophils. Numerous aetiological associations have been reported in the literature, including various haematological malignancies and drugs. Our case was peculiar because of association of capecitabine and Sweet syndrome in rectal cancer. We describe a case of a woman aged 57 years, with recently diagnosed stage III rectal cancer, developed painful erythematous rash over her face along with fever and headache...
December 23, 2016: BMJ Case Reports
https://www.readbyqxmd.com/read/28008656/human-herpesvirus-6-hhv-6b-lymphadenitis-in-dress-syndrome-a-lymphoma-mimic
#16
Steven Johnson, Stephanie Mathews, David S Hudnall
AIMS: Lymphadenopathy, hematologic abnormalities, and constitutional symptoms are among the non-specific manifestations seen in drug rash with eosinophilia and systemic symptoms (DRESS), an uncommon but potentially fatal cutaneous adverse drug reaction. The ubiquitous human herpesvirus 6 (HHV-6) plays a unique role in the pathogenesis of DRESS, with emerging data suggesting that reactivation occurs in most cases and contributes to the clinical manifestations, including lymphadenopathy...
December 23, 2016: Histopathology
https://www.readbyqxmd.com/read/28005146/-diagnostics-of-drug-hypersensitivity-reactions
#17
REVIEW
C Möbs, W Pfützner
Drug hypersensitivity reactions comprise approximately 25% of all adverse drug reactions and can be classified into allergic and pseudoallergic drug reactions. Immediate type anaphylactic and delayed type rash reactions of various clinical patterns can be distinguished, depending on the pathogenesis and clinical symptoms. The diagnostic work-up encompasses a thorough but also focused evaluation of the medical history, skin tests and when indicated challenge tests. Furthermore, in vitro tests, such as basophil activation tests and T cell assays not only add valuable additional information but can also yield decisive results for the diagnosis, especially in cases of severe drug reactions or reactions which cannot be further clarified by provocation tests...
December 22, 2016: Der Hautarzt; Zeitschrift Für Dermatologie, Venerologie, und Verwandte Gebiete
https://www.readbyqxmd.com/read/28000142/drug-reaction-with-eosinophilia-and-systemic-symptoms-dress-with-teicoplanin-a-case-report
#18
Sholeh Ebrahimpour, Mehdi Mohammadi, Kheirollah Gholami
Intramuscular teicoplanin (400 mg every 12 h for three doses, then 400 mg daily, intramuscularly) was prescribed for a 37-year-old woman with presumptive diagnosis of cellulitis. On the 14th day of treatment, she developed generalized maculopapular rash, accompanied by fever, wheezing, shortening of breath, and lymphadenopathy. Lab tests revealed abnormal liver enzymes, leukocytosis, and eosinophilia. The treatment was interrupted with suspicion of drug reaction. Fever subsided after 48 h. Skin eruption and respiratory symptoms began to resolve within 2 weeks...
December 2017: Drug Safety—Case Reports
https://www.readbyqxmd.com/read/27996289/cardiac-involvement-in-dress-syndrome
#19
Tomon Thongsri, Leena Chularojanamontri, Werner J Pichler
OBJECTIVE: Cardiac involvement in drug rash with eosinophilia and systemic symptoms (DRESS) syndrome varies considerably between 4% and 21%. Here we present our case and review literatures for its diagnosis and management. An algorithm for diagnosis of cardiac involvement in DRESS syndrome is proposed in this article. DATA SOURCES: Data regarding DRESS-associated myocarditis and eosinophilic myocarditis were gather primarily from MEDLINE database. RESULTS: DRESS syndrome is a hypersensitivity reaction which is due to massive T cell stimulation resulting in cytotoxicity and eosinophil activation and recruitment...
December 12, 2016: Asian Pacific Journal of Allergy and Immunology
https://www.readbyqxmd.com/read/27995212/is-this-a-simple-drug-eruption-to-be-discharged
#20
Mucahit Emet, Ilker Akbas, Esra Senturk, Omer Faruk Elmas, Sahin Aslan
'Erythema Multiforme associated with Phenytoin And Cranial radiation Therapy' (EMPACT) is a very rare clinic situation and classified in EM-like drug reactions. It can be easily misdiagnosed as acute urticaria or drug eruption in ED. Initial symptoms may resemble a simple skin problem, but diagnosing and early hospitalization of the patients can be lifesaving. Here, we present a man with renal cell cancer and brain metastases who admitted to ED due to fever and generalized rash. His skin lesions beginning from his head and spreading through the torso appeared four days after the end of radiotherapy (11 days after the initial dose of both radiation and oral phenytoin)...
December 2016: Turkish Journal of Emergency Medicine
keyword
keyword
87916
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"